Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNABW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ginkgo Bioworks Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ginkgo Bioworks Holdings's regulatory disclosures and financial reporting.
DNA filed a Form 144 reporting a proposed sale of Class A shares and recent small dispositions. The filing lists 40,893 Class A shares tied to a proposed sale and records two past dispositions of 2,200 shares on 02/04/2026 and 03/11/2026. The broker listed is Fidelity Brokerage Services LLC.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Filer reported sales of restricted Class A shares. The filing lists two recent dispositions by Bartholomew Canton: 13,155 shares on 04/08/2026 and 13,116 shares on 04/09/2026, with dollar amounts shown. The record also lists 124,727 shares associated with Fidelity Brokerage Services LLC and a total share figure of 49,941,878 as of 04/10/2026.
Issuer reported a Form 144 notice for the proposed sale of 13,116 Class A shares under Rule 144. The shares arose from Restricted Stock Vesting dated 04/08/2026 and are held at Fidelity Brokerage Services LLC.
The filing lists prior sales of 13,155 Class A shares by Bartholomew Canton on 04/08/2026 and shows 49,941,878 shares outstanding as of 04/09/2026.
Jason Kelly reports a proposed sale of 109,767 shares of Class A common stock under Form 144. The securities are tied to restricted stock vesting as compensation and dated 04/08/2026. The filing shows 97,015 shares sold during the past three months, with values listed as $702,201.45 and $672,343.05. Trades are noted for the NYSE and the filing header date is 04/09/2026.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings Inc: The Vanguard Group filed an Amendment No. 5 to its Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of Ginkgo Bioworks common stock. The filing explains an internal realignment effective 01/12/2026 that disaggregated certain Vanguard subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries under SEC Release No. 34-39538.
DNA submitted a Form 144 notice concerning Class A shares. The filing shows 708 Class A shares tied to a Restricted Stock Vesting event on 03/13/2026, with Fidelity Brokerage Services listed as broker. The filing also records a prior sale of 972 Class A shares on 01/20/2026 by Steve Coen.